ACM Global Central Laboratory Expands Global Footprint with Acquisition in Asia Pacific

ACM Global Central Laboratory have announced it has acquired Phoenix Pharma Central Services Pte Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed.
 

 
Established in 2001, Phoenix PCS is a highly respected central laboratory in Asia offering services for Phase I to Phase IV clinical trials, and has been accredited by the College of American Pathologists (CAP) since 2003. The company has an experienced staff with extensive knowledge of clinical trial operations, Asian cultures and regulatory requirements, and is well positioned to provide support to pharmaceutical and biotechnological industries in the development of drugs and medical devices.

 The ACM Singapore facility is located just five minutes from the Singapore International Airport and the city’s logistics hub. The laboratory in Shanghai is a brand new facility that has been purpose designed to optimise the company’s laboratory processes. Both laboratories will be equipped with ACM’s standard technology platforms and instrumentation to enable seamless integration with ACM Global’s operations in the United States, United Kingdom, and India, resulting in a single global database with harmonised test data for all global projects.